Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company engaged in the discovery development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.


Updates from The Motley Fool

Latest updates on Aerie Pharmaceuticals from Fool.com.


Stock Performance

View Interactive AERI Charts
Sponsored by

Key Data Points

Primary metrics and data points about Aerie Pharmaceuticals .
Current Price: $45.64
Prev Close: $47.09
Open: $47.04
Bid: $43.50
Ask: $47.91
Day's Range: $45.54 - $47.26
52wk Range: $32.18 - $74.75
Volume: 524,535
Avg Vol 854,100
Market Cap: $2B
P/E (ttm): -8.44
EPS (ttm): -$5.58
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Aerie Pharmaceuticals .
CAPS Rating 2 out of 5
 
24 Outperform
6 Underperform
CAPS All Stars
 
4 Outperform
5 Underperform

How do you think Aerie Pharmaceuticals will perform against the market?



You pick for Aerie Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Aerie Pharmaceuticals .

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company engaged in the discovery development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

  • Exchange: NASDAQ